Ahmed Gabr1, Ahsun Riaz1, Guy E Johnson2, Edward Kim3, Siddharth Padia4, Robert J Lewandowski1, Riad Salem5. 1. Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA. 2. Department of Radiology, Section of Interventional Radiology, University of Washington, Seattle, WA, USA. 3. Department of Radiology, Section of Interventional Radiology, Mount Sinai University Hospitals, New York, NY, USA. 4. Department of Radiology, Section of Interventional Radiology, University of California-Los Angeles, Los Angeles, CA, USA. 5. Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA. rsalem1@nm.org.
Abstract
PURPOSE: To study the correlation between absorbed perfused liver dose using Y90 radioembolization and degree of hepatocellular carcinoma (HCC) necrosis in liver explants in a multicenter cohort analysis METHODS: A retrospective analysis of 45 HCC patients treated between 2014 and 2017 is presented. Inclusion criteria were treatment-naïve solitary HCC ≤ 8 cm and Child-Pugh A liver status using the radiation segmentectomy approach. All patients underwent liver resection or transplantation (LT). Liver explants were examined per institutional routine protocols to assess histopathological viability of HCC. Tumor pathological necrosis was classified into complete (100% necrosis), extensive (> 50% and ≤ 99%) necrosis, and partial (< 50%) necrosis. Absorbed perfused liver doses were estimated using MIRD calculations. Associations between dose and degree of necrosis were studied. RESULTS: Thirty-four (76%) patients underwent LT, and 11 (24%) patients underwent hepatic resection. Median radiation dose was 240 (IQR: 136-387) Gy. Thirty (67%) patients had complete pathologic necrosis (CPN) at explant, while 10 (22%) and 5 (11%) had extensive and partial necrosis, respectively. There were significant differences among perfused liver doses that exhibited partial, extensive, and complete necrosis (p = 0.001). Twenty-four out of twenty-eight (86%) patients who had dose > 190 Gy achieved CPN, while 11/17 (65%) who had < 190 Gy did not (Fisher's exact test; p = 0.001). Using binary logistic regression, only absorbed radiation dose was significantly associated with CPN (p = 0.01), while tumor size was not (p = 0.35). All patients receiving > 400 Gy exhibited CPN. CONCLUSION: Radiation segmentectomy for early HCC with ablative dosing > 400 Gy results in CPN. This represents the new standard target dose for radiation segmentectomy.
PURPOSE: To study the correlation between absorbed perfused liver dose using Y90 radioembolization and degree of hepatocellular carcinoma (HCC) necrosis in liver explants in a multicenter cohort analysis METHODS: A retrospective analysis of 45 HCC patients treated between 2014 and 2017 is presented. Inclusion criteria were treatment-naïve solitary HCC ≤ 8 cm and Child-Pugh A liver status using the radiation segmentectomy approach. All patients underwent liver resection or transplantation (LT). Liver explants were examined per institutional routine protocols to assess histopathological viability of HCC. Tumor pathological necrosis was classified into complete (100% necrosis), extensive (> 50% and ≤ 99%) necrosis, and partial (< 50%) necrosis. Absorbed perfused liver doses were estimated using MIRD calculations. Associations between dose and degree of necrosis were studied. RESULTS: Thirty-four (76%) patients underwent LT, and 11 (24%) patients underwent hepatic resection. Median radiation dose was 240 (IQR: 136-387) Gy. Thirty (67%) patients had complete pathologic necrosis (CPN) at explant, while 10 (22%) and 5 (11%) had extensive and partial necrosis, respectively. There were significant differences among perfused liver doses that exhibited partial, extensive, and complete necrosis (p = 0.001). Twenty-four out of twenty-eight (86%) patients who had dose > 190 Gy achieved CPN, while 11/17 (65%) who had < 190 Gy did not (Fisher's exact test; p = 0.001). Using binary logistic regression, only absorbed radiation dose was significantly associated with CPN (p = 0.01), while tumor size was not (p = 0.35). All patients receiving > 400 Gy exhibited CPN. CONCLUSION: Radiation segmentectomy for early HCC with ablative dosing > 400 Gy results in CPN. This represents the new standard target dose for radiation segmentectomy.
Authors: Robert J Lewandowski; Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Ali Al Asadi; Ronald A Mora; Laura Kulik; Daniel Ganger; Kush Desai; Bartley Thornburg; Samdeep Mouli; Ryan Hickey; Juan Carlos Caicedo; Michael Abecassis; Ahsun Riaz; Riad Salem Journal: Radiology Date: 2018-04-24 Impact factor: 11.105
Authors: Derek M Biederman; Joseph J Titano; Vivian L Bishay; Raisa J Durrani; Etan Dayan; Nora Tabori; Rahul S Patel; Francis S Nowakowski; Aaron M Fischman; Edward Kim Journal: Radiology Date: 2016-12-07 Impact factor: 11.105
Authors: Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2013-10-01 Impact factor: 17.425
Authors: Ahsun Riaz; Laura Kulik; Robert J Lewandowski; Robert K Ryu; Georgia Giakoumis Spear; Mary F Mulcahy; Michael Abecassis; Talia Baker; Vanessa Gates; Ritu Nayar; Frank H Miller; Kent T Sato; Reed A Omary; Riad Salem Journal: Hepatology Date: 2009-04 Impact factor: 17.425
Authors: Ahmed Gabr; Srirajkumar Ranganathan; Samdeep K Mouli; Ahsun Riaz; Vanessa L Gates; Laura Kulik; Daniel Ganger; Haripriya Maddur; Christopher Moore; Elias Hohlastos; Nitin Katariya; Juan Carlos Caicedo; Aparna Kalyan; Robert J Lewandowski; Riad Salem Journal: J Hepatol Date: 2020-03-05 Impact factor: 25.083
Authors: Michael Vouche; Ali Habib; Thomas J Ward; Edward Kim; Laura Kulik; Daniel Ganger; Mary Mulcahy; Talia Baker; Michael Abecassis; Kent T Sato; Juan-Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Elias Hohlastos; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425
Authors: Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-17 Impact factor: 10.057
Authors: S Ali Montazeri; Cynthia De la Garza-Ramos; Andrew R Lewis; Jason T Lewis; Jordan D LeGout; David M Sella; Ricardo Paz-Fumagalli; Zlatko Devcic; Charles A Ritchie; Gregory T Frey; Lucas Vidal; Kristopher P Croome; J Mark McKinney; Denise Harnois; Sunil Krishnan; Tushar Patel; Beau B Toskich Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-20 Impact factor: 10.057
Authors: Cynthia De la Garza-Ramos; Cameron J Overfield; S Ali Montazeri; Harris Liou; Ricardo Paz-Fumagalli; Gregory T Frey; J Mark McKinney; Charles A Ritchie; Zlatko Devcic; Andrew R Lewis; Denise M Harnois; Tushar Patel; Beau B Toskich Journal: J Hepatocell Carcinoma Date: 2021-07-30